MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
18.30
+0.67
+3.80%
After Hours: 18.41 +0.11 +0.60% 19:25 07/16 EDT
OPEN
17.87
PREV CLOSE
17.63
HIGH
18.43
LOW
17.75
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
30.41
52 WEEK LOW
9.57
MARKET CAP
2.53B
P/E (TTM)
-13.2763
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARWR last week (0707-0711)?
Weekly Report · 2d ago
Arrowhead Pharmaceuticals Advances Phase 3 Study of Zodasiran for Cholesterol Management
TipRanks · 5d ago
Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Hypertriglyceridemia
TipRanks · 6d ago
Arrowhead doses first patient in YOSEMITE trial
TipRanks · 07/08 11:36
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of RNAi Therapeutic Zodasiran for Treating Homozygous Familial Hypercholesterolemia
Reuters · 07/08 11:30
ARROWHEAD PHARMACEUTICALS INITIATES PHASE 3 YOSEMITE STUDY OF INVESTIGATIONAL ZODASIRAN FOR THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Reuters · 07/08 11:30
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Barchart · 07/08 06:30
Weekly Report: what happened at ARWR last week (0630-0704)?
Weekly Report · 07/07 09:11
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.